Abbott's move came as somewhat of a surprise, but analysts have noted the potential for a trend in point-of-care diagnostics acquisitions.

Alere will become an Abbott subsidiary, and Alere shareholders will receive $56 per common share in cash at the completion of the transaction. 

The company reported $1.22 billion in Q4 Worldwide Diagnostics sales, including $126 million in molecular diagnostics sales due to growth in infectious disease testing.

Novacyt will validate its Novaprep liquid-based cytology platform with Abbott's RealTime High Risk human papillomavirus assay.

The virus, known as HPgV-2, was detected in blood samples from individuals with concurrent hepatitis C virus infections.

The amendment changes product fees Abbott pays to BG Medicine for galectin-3 test sales in exchange for making two payments totaling $1 million.

Abbott's third quarter diagnostic revenues shrunk 2 percent and molecular diagnostics sales dropped 5 percent, both due to unfavorable currency effects.

The test runs on the firm's m2000 PCR platform and is the first on the market to assess resistance to both rifampin and isoniazid.

Second quarter diagnostic revenues decreased 1 percent year over year to $1.18 billion as molecular diagnostics sales shrunk a fraction of a percent.

Under the agreement, Abbott will create tests for two protein biomarkers that AstraZeneca hopes can predict asthma patients' response to its investigational drug tralokinumab.


Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.